Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report)'s stock price fell 5.4% during trading on Thursday . The company traded as low as $2.61 and last traded at $2.62. 567,651 shares were traded during trading, a decline of 77% from the average session volume of 2,442,018 shares. The stock had previously closed at $2.77.
ALLO has been the topic of a number of recent analyst reports. Citigroup raised their price target on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Friday, August 9th. Canaccord Genuity Group reduced their price target on Allogene Therapeutics from $35.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, August 8th. Oppenheimer assumed coverage on Allogene Therapeutics in a report on Thursday, August 8th. They issued an "outperform" rating and a $11.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of Allogene Therapeutics in a research note on Thursday, August 15th. Finally, Truist Financial reaffirmed a "buy" rating and issued a $14.00 price target (down previously from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Allogene Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.96.
Get Our Latest Analysis on Allogene Therapeutics
The stock has a 50 day simple moving average of $2.68 and a 200-day simple moving average of $2.74. The firm has a market cap of $537.13 million, a PE ratio of -1.46 and a beta of 0.83.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.24%. As a group, equities analysts predict that Allogene Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its position in shares of Allogene Therapeutics by 76.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company's stock valued at $18,675,000 after buying an additional 1,806,147 shares during the last quarter. Renaissance Technologies LLC lifted its position in Allogene Therapeutics by 340.4% during the second quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company's stock valued at $4,073,000 after purchasing an additional 1,351,055 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in Allogene Therapeutics in the first quarter worth approximately $1,280,000. Dimensional Fund Advisors LP raised its stake in Allogene Therapeutics by 24.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company's stock valued at $5,944,000 after buying an additional 507,021 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Allogene Therapeutics by 70.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 480,381 shares of the company's stock valued at $1,119,000 after buying an additional 198,231 shares during the last quarter. Institutional investors own 83.63% of the company's stock.
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Allogene Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.
While Allogene Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.